DDInter1059 DDInter1376
Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in humans. First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults. While levomilnacipran was previously investigated and proposed as a potential treatment for stroke in Europe, the EMA decided against this use.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Levomilnacipran {u} (Compound) resembles {v} (Compound) Milnacipran
Levomilnacipran {u} (Compound) binds {v} (Gene) CYP2C19
Levomilnacipran {u} (Compound) is included by {v} (Pharmacologic Class) Serotonin Uptake Inhibitors
Levomilnacipran {u} (Compound) downregulates {v} (Gene) GJA1
Levomilnacipran {u} (Compound) causes {v} (Side Effect) Infection
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ramucirumab
Levomilnacipran {u} may lead to a major life threatening interaction when taken with {v} Doxepin
Levomilnacipran {u} may lead to a major life threatening interaction when taken with {v} Methylene blue
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Iobenguane
Levomilnacipran (Compound) resembles Milnacipran (Compound)
Levomilnacipran (Compound) binds CYP2C19 (Gene)
Levomilnacipran (Compound) is included by Serotonin Uptake Inhibitors (Pharmacologic Class)
Levomilnacipran (Compound) downregulates GJA1 (Gene)
Levomilnacipran (Compound) causes Infection (Side Effect)
Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Levomilnacipran may lead to a major life threatening interaction when taken with Doxepin
Levomilnacipran may lead to a major life threatening interaction when taken with Methylene blue
Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Levomilnacipran may lead to a major life threatening interaction when taken with Iobenguane